SurveyMonkey Powered Online Survey

About this survey

Thank you for participating.

This independent study by PatientView looks at the corporate reputation of the pharmaceutical industry (and that of 46 pharmaceutical companies) during 2024. 11 new pharmaceutical companies have been included for this 2024 survey.

You will be entitled to a free copy of the full results upon publication (April 2025), if you wish to receive them.

Note about the survey format:

If you are using a mobile/cell to answer the questionnaire, the survey is more easily completed when the mobile/cell is in LANDSCAPE.

This survey has 7 questions about your organisation, and 12 main questions. When you reach the end of the questionnaire, please click the “Submit” button to send it.

If you have any queries about this survey, the email contact is at the end of the survey.

Question Title

<div style="text-align: center;"> </div>

Question Title

* SEVEN PROFILING QUESTIONS

These profiling questions will help us understand the TYPES of organisations answering the survey, and allow us to make more sense of the results.

a.) Please note below (in your own choice of words) your organisation’s MAIN SPECIALTY.

Question Title

* b.) In which COUNTRY is your organisation based or headquartered?

(If you are a patient group with international scope, please respond on behalf of the country in which you, as a respondent, reside.)

Please select your country from the menu below.

Question Title

* c.) What is the GEOGRAPHIC REACH of your organisation?

International (if your organisation has representatives in MORE THAN ONE COUNTRY).

National.

Large regional (cantons; counties; provinces; states, etc, within one country).

Local.

Question Title

* d.) In the last 12 months, approximately HOW MANY PATIENTS did your organisation actively support and serve?

100 or less.

1,000 or less.

5,000 or less.

10,000 or less.

100,000 or less.

Over 100,000.

We do not communicate with patients directly.

I do not know.

Question Title

* e.) Below is a list of 46 top pharma companies worldwide
(including 11 companies new for this 2024 survey).

Can you indicate the companies with which your organisation has WORKED or co-operated?

AbbVie

Amgen (including Horizon)

Alnylam Pharmaceuticals

Angelini Pharma

Astellas Pharma

AstraZeneca (including Alexion)

Bayer

Biogen

BioMarin

Boehringer Ingelheim

Bristol Myers Squibb

Chiesi (including Amyrt)

Crinetics Pharmaceuticals

CSL Behring

Daiichi Sankyo

Eisai

Eli Lilly

Esteve Healthcare

Exelixis

Gilead Sciences (including Kite Pharma)

GSK

Incyte

Ipsen

Johnson & Johnson Innovative Medicine (formerly Janssen)

Jazz Pharmaceuticals

LEO Pharma

Lundbeck

Merck KGaA/EMD Serono

Merck & Co/MSD

Novartis

Novo Nordisk

Otsuka

Pfizer

PTC Therapeutics

Recordati

Regeneron Pharmaceuticals

Roche

Sanofi

Sarepta Therapeutics

Servier

Sobi

Takeda

UCB

Vertex

Viatris

ViiV Healthcare

If you would like to mention any other companies, you may do so here.

Question Title

* f.) If your organisation works or co-operates with pharma companies:
What are the MAIN TYPES of working or co-operating relationships your organisation has with pharma companies?

Providing grant funding.

Helping us to organise our events.

Inviting us to conferences or events.

Training us in advocacy.

Other types of training for us.

Providing information to us.

Support for our advocacy.

Support for our campaigns.

Co-creating projects with us.

Helping us create and design materials and support tools for patients.

Support with publicity for us.

Helping us network.

Support for our healthcare professionals.

Helping us conduct our own in-house non-medical research.

Involving us in company drug R&D (research and development).

Support in building our Web resources.

Help for us in the creation of our health apps.

None of the above.

I do not know.

Question Title

* g.) The same list of 46 pharma companies.

For the companies with which your organisation does not work:
Can you indicate the companies with which your organisation is FAMILIAR?

Please take the word ‘familiar’ to mean:
“Feeling knowledgeable enough about the company to be able to comment on its activities and products.”

AbbVie

Amgen/Horizon

Alnylam Pharmaceuticals

Angelini Pharma

Astellas Pharma

AstraZeneca/Alexion

Bayer

Biogen

BioMarin

Boehringer Ingelheim

Bristol Myers Squibb

Chiesi/Amyrt

Crinetics Pharmaceuticals

CSL Behring

Daiichi Sankyo

Eisai

Eli Lilly

Esteve Healthcare

Exelixis

Gilead Sciences/Kite Pharma

GSK

Incyte

Ipsen

J&J (Janssen)

Jazz Pharmaceuticals

LEO Pharma

Lundbeck

Merck KGaA/EMD Serono

Merck & Co/MSD

Novartis

Novo Nordisk

Otsuka

Pfizer

PTC Therapeutics

Recordati

Regeneron Pharmaceuticals

Roche

Sanofi

Sarepta Therapeutics

Servier

Sobi

Takeda

UCB

Vertex

Viatris

ViiV Healthcare

If you would like to mention any other companies, you may do so here.

Question Title

Questions on Corporate Reputation

For the purposes of this survey, please regard the phrase ‘corporate reputation’ to be defined as:

“The extent to which pharmaceutical companies are meeting the expectations of patients and patient groups.”

The survey has 12 main questions

Please skip any question that you cannot answer (or are irrelevant to your organisation).

Question Title

* FIRST, two questions about ...
the corporate reputation of the pharma industry as a whole

Question 1 of 12.
How does your organisation rate the corporate reputation of the following healthcare sectors in 2024?

	Excellent.	Good.	Fair.	Poor.	I do not know.
Biotechnology companies.	Biotechnology companies. Excellent.	Biotechnology companies. Good.	Biotechnology companies. Fair.	Biotechnology companies. Poor.	Biotechnology companies. I do not know.
Generic drug manufacturers.	Generic drug manufacturers. Excellent.	Generic drug manufacturers. Good.	Generic drug manufacturers. Fair.	Generic drug manufacturers. Poor.	Generic drug manufacturers. I do not know.
Health insurers (for-profit).	Health insurers (for-profit). Excellent.	Health insurers (for-profit). Good.	Health insurers (for-profit). Fair.	Health insurers (for-profit). Poor.	Health insurers (for-profit). I do not know.
Health insurers (not-for-profit).	Health insurers (not-for-profit). Excellent.	Health insurers (not-for-profit). Good.	Health insurers (not-for-profit). Fair.	Health insurers (not-for-profit). Poor.	Health insurers (not-for-profit). I do not know.
Medical-device companies.	Medical-device companies. Excellent.	Medical-device companies. Good.	Medical-device companies. Fair.	Medical-device companies. Poor.	Medical-device companies. I do not know.
Pharmaceutical companies (multinational).	Pharmaceutical companies (multinational). Excellent.	Pharmaceutical companies (multinational). Good.	Pharmaceutical companies (multinational). Fair.	Pharmaceutical companies (multinational). Poor.	Pharmaceutical companies (multinational). I do not know.
Pharmacy Benefit Managers (PBMs)—if relevant in your country.	Pharmacy Benefit Managers (PBMs)—if relevant in your country. Excellent.	Pharmacy Benefit Managers (PBMs)—if relevant in your country. Good.	Pharmacy Benefit Managers (PBMs)—if relevant in your country. Fair.	Pharmacy Benefit Managers (PBMs)—if relevant in your country. Poor.	Pharmacy Benefit Managers (PBMs)—if relevant in your country. I do not know.
Private-sector healthcare services.	Private-sector healthcare services. Excellent.	Private-sector healthcare services. Good.	Private-sector healthcare services. Fair.	Private-sector healthcare services. Poor.	Private-sector healthcare services. I do not know.
Retail pharmacists.	Retail pharmacists. Excellent.	Retail pharmacists. Good.	Retail pharmacists. Fair.	Retail pharmacists. Poor.	Retail pharmacists. I do not know.

Would you like to comment on your answer?

Question Title

* Question 2 of 12.
How “good” or “bad” do you think the pharmaceutical industry as a whole has been in 2024 at carrying out the following activities (all of which influence the industry’s corporate standing with patients and patient groups)?

	Excellent.	Good.	Fair.	Poor.	I do not know.
Having a patient-centred strategy.	Having a patient-centred strategy. Excellent.	Having a patient-centred strategy. Good.	Having a patient-centred strategy. Fair.	Having a patient-centred strategy. Poor.	Having a patient-centred strategy. I do not know.
Providing high-quality information for patients.	Providing high-quality information for patients. Excellent.	Providing high-quality information for patients. Good.	Providing high-quality information for patients. Fair.	Providing high-quality information for patients. Poor.	Providing high-quality information for patients. I do not know.
Ensuring patient safety.	Ensuring patient safety. Excellent.	Ensuring patient safety. Good.	Ensuring patient safety. Fair.	Ensuring patient safety. Poor.	Ensuring patient safety. I do not know.
Being innovative.	Being innovative. Excellent.	Being innovative. Good.	Being innovative. Fair.	Being innovative. Poor.	Being innovative. I do not know.
Making products that are of benefit to patients.	Making products that are of benefit to patients. Excellent.	Making products that are of benefit to patients. Good.	Making products that are of benefit to patients. Fair.	Making products that are of benefit to patients. Poor.	Making products that are of benefit to patients. I do not know.
Being transparent about company pricing policies.	Being transparent about company pricing policies. Excellent.	Being transparent about company pricing policies. Good.	Being transparent about company pricing policies. Fair.	Being transparent about company pricing policies. Poor.	Being transparent about company pricing policies. I do not know.
Being transparent by sharing clinical data.	Being transparent by sharing clinical data. Excellent.	Being transparent by sharing clinical data. Good.	Being transparent by sharing clinical data. Fair.	Being transparent by sharing clinical data. Poor.	Being transparent by sharing clinical data. I do not know.
Being transparent by disclosing the funding of stakeholders (such as doctors or patient groups).	Being transparent by disclosing the funding of stakeholders (such as doctors or patient groups). Excellent.	Being transparent by disclosing the funding of stakeholders (such as doctors or patient groups). Good.	Being transparent by disclosing the funding of stakeholders (such as doctors or patient groups). Fair.	Being transparent by disclosing the funding of stakeholders (such as doctors or patient groups). Poor.	Being transparent by disclosing the funding of stakeholders (such as doctors or patient groups). I do not know.
Acting with integrity.	Acting with integrity. Excellent.	Acting with integrity. Good.	Acting with integrity. Fair.	Acting with integrity. Poor.	Acting with integrity. I do not know.
Working in partnership with patient groups.	Working in partnership with patient groups. Excellent.	Working in partnership with patient groups. Good.	Working in partnership with patient groups. Fair.	Working in partnership with patient groups. Poor.	Working in partnership with patient groups. I do not know.
Providing patients with more services than just the provision of medicines.	Providing patients with more services than just the provision of medicines. Excellent.	Providing patients with more services than just the provision of medicines. Good.	Providing patients with more services than just the provision of medicines. Fair.	Providing patients with more services than just the provision of medicines. Poor.	Providing patients with more services than just the provision of medicines. I do not know.
Fair pricing policies.	Fair pricing policies. Excellent.	Fair pricing policies. Good.	Fair pricing policies. Fair.	Fair pricing policies. Poor.	Fair pricing policies. I do not know.
Engaging patients/patient groups in company drug R&D (research and development).	Engaging patients/patient groups in company drug R&D (research and development). Excellent.	Engaging patients/patient groups in company drug R&D (research and development). Good.	Engaging patients/patient groups in company drug R&D (research and development). Fair.	Engaging patients/patient groups in company drug R&D (research and development). Poor.	Engaging patients/patient groups in company drug R&D (research and development). I do not know.
Helping more patients gain access to medicines.	Helping more patients gain access to medicines. Excellent.	Helping more patients gain access to medicines. Good.	Helping more patients gain access to medicines. Fair.	Helping more patients gain access to medicines. Poor.	Helping more patients gain access to medicines. I do not know.

Would you like to comment on your answer?

Question Title

Please click “Next”, below, to move on to the company-specific questions.

About this survey

Question Title

Question Title

* SEVEN PROFILING QUESTIONSThese profiling questions will help us understand the TYPES of organisations answering the survey, and allow us to make more sense of the results.a.) Please note below (in your own choice of words) your organisation’s MAIN SPECIALTY.

Question Title

Question Title

* b.) In which COUNTRY is your organisation based or headquartered?(If you are a patient group with international scope, please respond on behalf of the country in which you, as a respondent, reside.)Please select your country from the menu below.

Question Title

Question Title

* c.) What is the GEOGRAPHIC REACH of your organisation?

Question Title

Question Title

* d.) In the last 12 months, approximately HOW MANY PATIENTS did your organisation actively support and serve?

Question Title

Question Title

* e.) Below is a list of 46 top pharma companies worldwide(including 11 companies new for this 2024 survey).Can you indicate the companies with which your organisation has WORKED or co-operated?

Question Title

Question Title

* f.) If your organisation works or co-operates with pharma companies:What are the MAIN TYPES of working or co-operating relationships your organisation has with pharma companies?

Question Title

Question Title

Question Title

Question Title

* FIRST, two questions about ...the corporate reputation of the pharma industry as a wholeQuestion 1 of 12.How does your organisation rate the corporate reputation of the following healthcare sectors in 2024?

Question Title

Question Title

* Question 2 of 12.How “good” or “bad” do you think the pharmaceutical industry as a whole has been in 2024 at carrying out the following activities (all of which influence the industry’s corporate standing with patients and patient groups)?

Question Title

* SEVEN PROFILING QUESTIONS

These profiling questions will help us understand the TYPES of organisations answering the survey, and allow us to make more sense of the results.

a.) Please note below (in your own choice of words) your organisation’s MAIN SPECIALTY.

* b.) In which COUNTRY is your organisation based or headquartered?

(If you are a patient group with international scope, please respond on behalf of the country in which you, as a respondent, reside.)

Please select your country from the menu below.

* e.) Below is a list of 46 top pharma companies worldwide
(including 11 companies new for this 2024 survey).

Can you indicate the companies with which your organisation has WORKED or co-operated?

* f.) If your organisation works or co-operates with pharma companies:
What are the MAIN TYPES of working or co-operating relationships your organisation has with pharma companies?

* FIRST, two questions about ...
the corporate reputation of the pharma industry as a whole

Question 1 of 12.
How does your organisation rate the corporate reputation of the following healthcare sectors in 2024?

* Question 2 of 12.
How “good” or “bad” do you think the pharmaceutical industry as a whole has been in 2024 at carrying out the following activities (all of which influence the industry’s corporate standing with patients and patient groups)?